The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by HC Wainwright & Co. on November 25, 2024. The analyst firm set a price target for $15.00 expecting ABEO to rise to within 12 months (a possible 163.16% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by HC Wainwright & Co., and Abeona Therapeutics reiterated their buy rating.

There is no last upgrade for Abeona Therapeutics

There is no last downgrade for Abeona Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on November 25, 2024 so you should expect the next rating to be made available sometime around November 25, 2025.

While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $15.00 to $15.00. The current price Abeona Therapeutics (ABEO) is trading at is $5.70, which is out of the analyst’s predicted range.